Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;93(6):739-746.
doi: 10.1016/j.mayocp.2018.02.011. Epub 2018 Apr 12.

Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review

Robert A Kyle  1 , Dirk R Larson  2 , Ellen D McPhail  3 , Terry M Therneau  2 , Angela Dispenzieri  4 , Shaji Kumar  4 , Prashant Kapoor  4 , James R Cerhan  5 , S Vincent Rajkumar  4
Affiliations

Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review

Robert A Kyle et al. Mayo Clin Proc. 2018 Jun.

Abstract

Objective: To determine the incidence of Waldenström macroglobulinemia (WM) in a strictly defined geographic area over a 50-year period.

Patients and methods: All residents of Olmsted County with a diagnosis of WM, consisting of a monoclonal IgM protein of any size and/or 10% or more lymphoplasmacytic infiltration of the bone marrow along with anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly requiring therapy, were identified from January 1, 1961, to December 31, 2010. Patients with smoldering WM, lymphoplasmacytic lymphoma with an IgG or IgA monoclonal protein, and those with an IgM monoclonal gammopathy of undetermined significance were excluded. The peripheral blood smears, bone marrow aspirates, and biopsy specimens were reviewed by an experienced hematopathologist.

Results: Twenty-two patients were identified as having WM. The age-adjusted incidence rate for males was 0.92 per 100,000 person-years (95% CI, 0.44-1.39 per 100,000 person-years) and for females was 0.30 per 100,000 person-years (95% CI, 0.08-0.53 per 100,000 person-years) with an age- and sex-adjusted incidence of 0.57 per 100,000 person-years (95% CI, 0.33-0.81 per 100,000 person-years). When evaluated using a smoothing spline, there was no convincing evidence for a change in the incidence of WM over the past 50 years. Patients diagnosed with WM after 2000 had an approximately 2-fold excess mortality compared with the expected population mortality (standardized mortality ratio, 2.4; 95% CI, 0.64-6.0).

Conclusion: Waldenström macroglobulinemia is a rare malignancy, and the incidence in Olmsted County, Minnesota, has shown virtually no change over the past 50 years.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: The other authors have nothing to disclose.

Figures

Figure 1
Figure 1
Age and Sex-Adjusted Incidence Rates of Waldenström Macroglobulinemia per 100,000 Person-Years in Olmsted County, Minnesota, 1961 through 2010.
Figure 2
Figure 2
Age and Sex-Adjusted Incidence Rates of Waldenström Macroglobulinemia per 100,000 Person-Years in Olmsted County, Minnesota by Decade, 1961 through 2010.
See this image and copyright information in PMC

References

    1. King RL, Gonsalves WI, Ansell SM, et al. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. Am J Clin Pathol. 2016;145(6):843–851. - PubMed
    1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. - PubMed
    1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9. - PMC - PubMed
    1. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology. 2003;30(2):116–120. [Review] [17 refs] - PubMed
    1. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood. 2012;119(19):4462–4466. - PMC - PubMed

Publication types